Published in Oncoimmunology on October 22, 2013
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Novel immunotherapies for hematologic malignancies. Immunol Rev (2015) 0.90
Immunotherapy for malignant glioma. Surg Neurol Int (2015) 0.81
Are BiTEs the "missing link" in cancer therapy? Oncoimmunology (2015) 0.81
Antibody-based immunotherapy for malignant glioma. Semin Oncol (2014) 0.80
Anti-GITR therapy promotes immunity against malignant glioma in a murine model. Cancer Immunol Immunother (2016) 0.78
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology (2015) 0.77
Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology (2016) 0.76
Tregs activated by bispecific antibodies: Killers or suppressors? Oncoimmunology (2015) 0.75
Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. Pediatr Blood Cancer (2015) 0.75
Targeting Malignant Brain Tumors with Antibodies. Front Immunol (2017) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 15.04
Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity (2004) 4.11
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther (2011) 1.45
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci U S A (2012) 1.44
EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol (2009) 1.40
Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody. Cancer Immunol Res (2013) 0.94
A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system. Oncoimmunology (2013) 0.87
An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. Expert Rev Clin Pharmacol (2013) 0.84
Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. J Immunol Methods (2013) 0.83